...antibodies to treat HIV. DYAX will use its antibody libraries to identify anti-R7V candidates, and Urrma...
...equally share commercialization rights and profits. The companies also have the option to jointly develop Urrma's...
...fee in return for a 45% interest in resulting products. Dyax Corp. (DYAX), Cambridge, Mass. Urrma Biopharma Inc....

...Urrma began a study of its anti-R7V test in 1,450 patients. Urrma Biopharma Inc. , Montreal, Quebec Product...

...FOR exercised an option to purchase C$1 million (US$621,000) of Urrma stock. FOR previously invested C$2...
...has an option to invest an additional C$1 million. Franc-Or Resources Corp. (TSE:FOR), Montreal, Quebec Urrma Biopharma Inc....